IMCR
Immunocore Holdings plc
IMCR lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
IMCR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
IMCR's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
IMCR PE Valuation
IMCR has no meaningful PE right now: it lost money over the past year.
IMCR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IMCR's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
IMCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.66 | -$0.09 |
| Q2 2026 | -$0.38 | +$0.02 |
| Q1 2026 | -$0.56 | -$0.13 |
| Q4 2025 | -$0.71 | +$0.31 |
| Q3 2025 | -$0.57 | +$0.41 |
| Q2 2025 | -$0.40 | +$0.70 |
| Q1 2025 | -$0.43 | +$0.82 |
| Q4 2024 | -$1.02 | +$0.21 |
IMCR is still losing money, but far less than before: $0.66 per share over the past year, against $4.12 at its worst in late 2021.
IMCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $102.2M | -1.4% |
| Q2 2026 | $115.9M | +18% |
| Q1 2026 | $106.7M | +14% |
| Q4 2025 | $104.5M | +24% |
| Q3 2025 | $103.7M | +29% |
| Q2 2025 | $98M | +30% |
| Q1 2025 | $93.9M | +33% |
| Q4 2024 | $84.1M | +13% |
IMCR's revenue is growing: $102M last quarter, down 1.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -13% | -6.4 points |
| Q2 2026 | -2.6% | +13 points |
| Q1 2026 | 6.8% | +11 points |
| Q4 2025 | -19% | +4.3 points |
| Q3 2025 | -6.9% | +3.7 points |
| Q2 2025 | -15% | +6.1 points |
| Q1 2025 | -3.9% | +34 points |
| Q4 2024 | -23% | +1.2 points |
IMCR's operating margin was −13% last quarter, down 6.4 points from the same quarter a year ago.
IMCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $17.7M | +$22.9M |
| Q2 2026 | $15.1M | -41% |
| Q1 2026 | -$15.6M | -11455% |
| Q4 2025 | -$35.5M | -$18M |
| Q3 2025 | -$5.2M | -126% |
| Q2 2025 | $25.6M | +10% |
| Q1 2025 | $137K | +$5.2M |
| Q4 2024 | -$17.5M | +$1M |
IMCR has burned cash in most quarters: −$18M over the past year, against $3M the year before.
IMCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +585K shares |
| 1 year | +2.3% | +1.2M shares |
| 3 years | -4.8% | -2.6M shares |
| 5 years | +18% | +7.8M shares |
| Available history | +89% | +24.3M shares |
IMCR has 52M diluted shares, up 2.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
IMCR Net Leverage
IMCR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IMCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 30.2 | Neutral |
IMCR's weekly RSI is 45 (neutral) and its Stochastic is 30 (neutral).
IMCR PE vs Healthcare Sector
IMCR has no meaningful PE right now: it lost money over the past year.
IMCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $30.3 | 0.7% above |
| 20 week MA | $32.6 | 6.6% below |
| 50 week MA | $32.1 | 5% below |
| 100 week MA | $32.1 | 5.1% below |
| 200 week MA | $42.0 | 27% below |
IMCR has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 27% below its 200-week average.
IMCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $43.2 | $35.4 | -18% |
| 2022 | $35.4 | $57.8 | +63% |
| 2023 | $57.8 | $68.3 | +18% |
| 2024 | $68.3 | $29.2 | -57% |
| 2025 | $29.2 | $36.1 | +24% |
| 2026 YTD | $36.1 | $30.5 | -16% |
IMCR has finished higher in three of the last five years. It's down 16% so far in 2026.